re: vcr to receive $125k us per patient from Fosters ---
US Strategy. We believe that the commencement of this trial will
trigger greater interest from US investors. VCR CEO Colin Sutton has
recently returned from a US roadshow, and we believe further US
roadshows are likely in the near term. VCR is also creating a greater
permanent presence in the US, having appointed a new US COO, Peter
Crosby, who is currently recruiting key staff. Once this current US
study is completed, VCR is expected to commence its final US trial.
§ European Strategy. VCR is continuing its CE Mark trials for approval in
Europe. Patient enrollment for this trial is expected to be completed
by the end of the year, once the final device is implanted. The results
of this trial should be released in H2 FY06 with European approval
expected around the middle of next year.
VCR
ventracor limited
